LAUSR

BACKGROUND The efficacy of antibiotic utilization following reduction mammaplasty has not been well studied. Furthermore, there is a lack of data describing subgroups who are historically high-risk for surgical site infection (SSI), specifically the obese population. OBJECTIVES This study compares SSI rates in reduction mammaplasty patients that received postoperative courses of antibiotics to those that did not. Additional analysis was performed for the subgroup of patients with body mass index (BMI) ≥30 kg/m2. METHODS The 2010 to 2021 PearlDiver Mariner dataset (PearlDiver Inc, Colorado Springs, CO) was reviewed to identify reduction mammaplasty patients. Patients were confirmed to have received perioperative antibiotics. Postoperative antibiotic use was determined based on the presence of postoperative prescriptions, and 1:1 matching was performed for those with and without postoperative antibiotics based on age and Elixhauser Comorbidity Index. Ninety-day rates of SSI, emergency department (ED) visits, and readmissions were recorded and compared. A subgroup analysis was performed on patients with BMI ≥30 kg/m2. RESULTS Among patients that were confirmed to receive perioperative antibiotics, 2230 patients that also received postoperative antibiotics were identified and matched to 2230 patients that did not. Rates of SSI, ED visits, and readmission were not statistically different. 218 obese patients were identified from this group and matched. Rates of SSI, ED visits, and readmission were not statistically different. CONCLUSIONS The current study found no difference in SSI rates between patients that received postoperative antibiotics and those that did not. These observations are corroborated in the obese population. These data may assist surgeons when considering postoperative antibiotics in reduction mammaplasty.